Skip to main content

Advertisement

We’d like to understand how you use our websites in order to improve them. Register your interest.

Unveiling ncRNA regulatory axes in atherosclerosis progression

Abstract

Completion of the human genome sequencing project highlighted the richness of the cellular RNA world, and opened the door to the discovery of a plethora of short and long non-coding RNAs (the dark transcriptome) with regulatory or structural potential, which shifted the balance of pathological gene alterations from coding to non-coding RNAs. Thus, disease risk assessment currently has to also evaluate the expression of new RNAs such as small micro RNAs (miRNAs), long non-coding RNAs (lncRNAs), circular RNAs (circRNAs), competing endogenous RNAs (ceRNAs), retrogressed elements, 3′UTRs of mRNAs, etc. We are interested in the pathogenic mechanisms of atherosclerosis (ATH) progression in patients suffering Chronic Kidney Disease, and in this review, we will focus in the role of the dark transcriptome (non-coding RNAs) in ATH progression. We will focus in miRNAs and in the formation of regulatory axes or networks with their mRNA targets and with the lncRNAs that function as miRNA sponges or competitive inhibitors of miRNA activity. In this sense, we will pay special attention to retrogressed genomic elements, such as processed pseudogenes and Alu repeated elements, that have been recently seen to also function as miRNA sponges, as well as to the use or miRNA derivatives in gene silencing, anti-ATH therapies. Along the review, we will discuss technical developments associated to research in lncRNAs, from sequencing technologies to databases, repositories and algorithms to predict miRNA targets, as well as new approaches to miRNA function, such as integrative or enrichment analysis and their potential to unveil RNA regulatory networks.

Background. Atherosclerosis progression and the dark transcriptome

Atherosclerosis (ATH) is a complex inflammatory disease of the vessel wall caused by a combination of multiple factors including genomics, epigenetic modifications and environmental conditions, that place an enormous burden on modern societies, particularly in the aging population [1]. The complexity of its causes and mechanisms makes ATH prevention and treatment largely ineffective, becoming an enormous challenge for our society, favored by our lifestyle [2, 3]. Thus, there is an urgent need to develop a more personalized medicine, and to enhance patient care through improved diagnostic sensitivity with more effective interventions in ATH prevention and treatment [4]. In this sense, years of research on the genomic basis of ATH have provided the biomedical community with a knowledge of gene-related ATH risk factors, such as SNPs [5, 6], genes and gene variants [7,8,9], alterations in DNA methylation [10, 11], changes in gene expression [12, 13], etc. Nevertheless, in the last years a new player has entered the game of disease-associated genes: the highly heterogeneous group of non-coding RNAs, which are progressively becoming important factors for atherosclerosis (and other diseases) research either as biomarkers of disease progression or as pathophysiological intermediates, while their operative interactions highlight the remarkable structural and functional complexity of the human genome.

From junk to gold, non-coding RNAs are functional components of the human transcriptome

Analysis of the sequenced human genome showed that over 80% of the genome could be considered as biochemically active [14], most of it in the form of DNase I-accessible loci or candidate regulatory sequences [15,16,17]. Although the number of protein coding genes in the human genome has been recently estimated at 20–25,000 [18, 19], the total number of active genomic loci is significantly higher, with a best guess being close to 10e5 [20] most of them corresponding to a plethora of heterogeneous, non-protein-coding, RNAs [21]. Originally considered as part of the “dark transcriptome” or “genomic dark matter”, i.e. genomic sequences of uncertain or unknown function [22, 23], non-coding RNAs were initially classified by their length into short (< 200 nucleotides long) and long (lncRNAs, > 200 nucleotides long) RNAs. Although some efforts have been devised to make a more informative and standardized nomenclature of ncRNAs [24, 25], this primary classification based in length is still widely accepted by the scientific community, and we will follow this convention in this review. Short ncRNAs include the already known snRNAs, snoRNAs and tRNAs, the PIWI-associated RNAs that repress expression of transposable and repetitive elements in the germline to maintain genomic stability [26] and the microRNA (miRNA) family of translational regulators (see the “MicroRNAS (miRNAs), a family of pleiotropic translational regulators” section here and [27] for a review). On the other hand, lncRNAs conformed a highly heterogeneous group in size and function, with regulatory roles in development, differentiation and disease progression [28,29,30,31], and whose expression is frequently altered in disease (see “Long non-coding RNAs (lncRNAs) and their functional relationship with miRNAs” section here and [32] for a review).

Data on the expression of non-coding RNAs have drawn a new model of the human genome function in which the nucleus is pervasively transcribed, even in intronic and intergenic sites [33], to generate a complex population of short and long non-coding RNAs with putative regulatory functions [34]. Although this model has been challenged on technical bases [35, 36], it is now widely accepted that in the mammalian genome over one order of magnitude more genomic sequence is transcribed to non-coding RNA than to protein-coding RNA [37]. This new model has also changed the original paradigm on the flow of genetic information from the linear “DNA makes RNA makes protein”, for many years considered as the central dogma of molecular biology [38, 39], to a multilayered process characterized by the pervasive expression of many structural or regulatory RNAs with the ability to establish different tiers of functional interactions (Fig. 1). This change of paradigm has had a number of consequences, such as the exponential increase in the number of non-protein coding RNAs associated to diseases, drawing new layers of epigenetic control that confer regulatory plasticity and are deregulated in disease, and the need to profile and give sense to these expression alterations and to the huge amount of expression data generated by disease-associated sequencing projects.

Fig. 1
figure1

The “central dogma” revisited. Shown are new additions to the central dogma (boxed), highlighting the fundamental role of miRNAs in the regulation of gene expression. This work reviews the functional relationships among the RNAs drawn in red. Black arrows means transcription or translation, double-headed red arrows mean mutual interactions, red arrows functional interactions (in the case of pseudogenes and Alu elements, retroinsertion) and dotted lines refer to the histone code and chromatin modifications

Our group is interested in the role of ncRNAs in the context of ATH progression. Here, we will review recent developments on the impact of non-coding RNAs on ATH progression, focusing on the role of microRNAs. We will also study their functional relationship with lncRNAs, since these have been reported to play key functions in physiology and disease [40], and to have a role in miRNA function as miRNA “sponges” or competitive inhibitors of miRNA activity. Furthermore, in this group of lncRNAs we will also include other transcripts, such as pseudogenes, and expressed Alu elements, which have been reported to also interact with miRNAs but that have been less studied.

DNA sequencing and the integration of transcriptomics with personalized medicine

In less than 25 years, DNA sequencing [41, 42] evolved from a technique only available to the elite of basic research laboratories to a tool widely used in clinical settings, a technical evolution that crystallized in the sequencing of the human genome by two scientific consortia [43, 44] and opened the age of the personalized genomic medicine. Today, systematic DNA sequencing of whole genomes or exomes is performed in all branches of medicine as a prognostic or diagnostic tool, or to follow treatment or disease progression. Furthermore, single-cell RNA-sequencing (scRNA-seq) methodologies allow the genome-wide profiling of individual cells to identify mutations and to characterize and quantify cellular heterogeneity and its variations in disease [45].

Open sequence repositories, the key to the sequencing revolution

One key factor of success of the sequencing revolution has been the almost immediate accessibility to all sequences generated in research laboratories, many times even prior to publication. This was possible because of the establishment of three mirrored sequence repositories (GenBank at the NCBI, DNA DataBank of Japan and the European Nucleotide Archive, Table 1) that stored, annotated and provided public and unrestricted access to all DNA and RNA sequences in the context of the International Nucleotide Sequence Database Collaboration [46]. One critical point of these repositories is that these not only facilitated the diffusion of DNA/RNA sequences by giving each one of them a unique sequence identifier, but also created a database of “reference genomes”, a collection of non-redundant, reference genomic, transcriptomic and protein sequences, intended to function as primary sequence references in genomic works [47, 48]. Furthermore, these also provided diverse annotations to the sequences, from functional domains to genomic loci, intended as maps of the genomic landscape to facilitate the interpretation of the genomic context of a specific sequence [20]. Lastly, all these information have been integrated in “genomic browsers” (Ensembl [49], and NCBI’s genome viewer [50]) which allow users going from chromosome regions to the sequence of any transcriptional unit and its variants.

Table 1 Sequence databases and repositories

The revolution in sequencing technologies

Initial sequencing protocols used ultrathin PAGE gels to resolve radioactively-labelled fragments [51, 52]. Although DNA sequencing was subsequently improved by the introduction of fluorescent labels [53] and by the use of the thermostable Taq DNA polymerase [54, 55], these methods were not adaptable to the high throughput-approach requisites of clinical sequencing. In this context, sequencing of the human genome started a race for new methods and faster and cheaper sequencing machines, with the objective set at the “1000 $ genome” [56], that prompted different approaches to the high-throughput sequencing of DNA. Aside of the pore sequencing (Oxford Nanopore) that perform a direct sequencing by using protein nanopores without DNA synthesis or amplification [57], most of the current sequencing platforms use a highly/mass parallel approach [58]. In this approach, the original sample (genomic DNA for genome sequencing or RNA copied as cDNA for exome sequencing) is fragmented and the fragments immobilized in individual cells where they are amplified, cycle-copied with labeled nucleotides and each reaction is individually detected as fluorescence (Illumina, Qiagen Gene reader or Pacbio platforms), or as H+ (Ion torrent platform). Lastly, each sequence is compared with reference genomes or exomes for identification [58].

The technical challenge of sequencing ncRNAs

Sequencing ncRNAs suppose a technical challenge derived of their heterogeneous length and exonic composition since these have sizes ranging from the 22 nucleotides of mature miRNAs [59] to the 22.7 kb of the single exon NEAT1_v2 transcript [60]. One possibility to overcome this problem is performing short sequence reads, like the expressed sequence tags (ESTs) in which individual cDNA clones were sequenced by their 3′ end only, generating reads of a few hundred nucleotides that were as “tags” of the full-length transcript [61]. Although this approach is suitable for the construction of genetic and physical maps of expressed sequences [62,63,64], it would not detect all the richness of CDS mutations (required for cancer research) or the complex patterns of alternative splicing that display lncRNAs. In this sense, and as an example, the relatively “short” 3.8 kb ANRIL [65], is expressed as over 50 splicing isoforms, linear or circular [66, 67], some of them disease-related [68]. In this complex context it is evident that recovering most of the lncRNA genomic information will require not only developing new sequencing hardware able to provide longer and more accurate reads, but also to improve the ability of reverse transcriptase (RT) to copy as much as possible of the full-length sequence, although these problems could be circumvented by a more “classical” molecular biology approach using random primers for the RT reaction, followed by the painstaking growth of the sequence by the 5′/3′ RACE (rapid amplification of cDNA ends) technique [69].

On the other hand, and for the case of small miRNAs, the entire population of a tissue can be sequenced by gel-purifying the fraction of small RNAs, adding them 5′ and 3′ adaptors with T4 RNA ligase, followed by a reverse transcription and PCR amplification prior to sequencing in any of the above platforms. In this way, representative results are obtained even for low expressed miRNAs, since the number of reads is proportional to the number of initial miRNA copies [70]. Furthermore, when dealing with miRNAs, the new high-throughput sequencing techniques have the potential to provide single-nucleotide resolution of miRNA species, facilitate de novo miRNA discovery and offer a dynamic range for miRNA quantification [71].

MicroRNAS (miRNAs), a family of pleiotropic translational regulators

MiRNAs are small RNAs (over 22 nucleotides long) with important roles in post-transcriptional gene regulation [59]. MiRNA genes are under transcriptional control, are transcribed by RNA polymerase II and suffer a process of maturation from pri-miRNA primary transcripts to the fully functional mature miRNAs which include activity of RNase III endoribonucleases DROSHA and DICER (see [72, 73] for reviews). In a recent work, Alles et al. estimated the entire human miRNAome as being composed by 2300 mature miRNAs of which 1115 were annotated in the version 22 of the specific miRNA database, miRbase [74]. MiRNAs function by targeting mRNAs, usually by base-pairing at their 3′UTR, for degradation or translational repression through the RISC complex (RNA Induced Silencing Complex) [27]. Recent reports estimated that over 60% of mRNAs harbour miRNA binding sites at their 3′UTRs, highlighting the importance of this interaction for the fine-tuning regulation of translation [75, 76]. An interesting characteristic of miRNA function is their functional promiscuity. Since only 6 bases of miRNA/mRNA complementarity are enough for duplex formation [77], a single miRNA can target dozens of different mRNAs which in turn can be regulated by many different miRNAs, thus creating a complex regulatory network [78].

Dynamics of 3′UTRs: more than a counterpart for miRNA function

3′UTR regions of mRNAs are highly polymorphic in length and sequence, variations that may underlie changes in miRNA targeting and stability of the involved mRNAs [79]. Length polymorphisms of 3′UTRs are due to two different mechanisms: alternative splicing of untranslated exons, which is shared with most RNAs, and alternative polyadenylation, which seems to be mostly restricted to mRNAs, lincRNAs and NATs [80]. In a seminal work, Liaw et al. showed that cancer cells expressed shorter 3′UTRs than normal cells [81], suggesting that 3′UTR lengthening could constitute a mechanism to control accessibility to miRNA sites whose de-regulation could result in disease [82, 83], and suggesting that the 3′UTRome should be studied not only as a catalogue of miRNA binding sites but as a dynamic structure whose de-regulated changes could lead to the identification of new risk factors, or new candidates for disease genes [83]. Nevertheless, the effects of 3′UTR heterogeneity on the patterns of miRNA binding is a poorly studied topic, despite its potential importance, and there are only a few reports published. Without the aim of being exhaustive, since this topic will be treated more in deep in another work (Navarro et al. in progress), there are published examples on the regulation of miRNA activity by alternative 3′UTRs. In this sense, Xiao et al., showed that alternative polyadenylation at the 3′UTR of AAMDC originated two isoforms that differed in length and that only the long isoform was susceptible to miR-2428/664a silencing [84], while Bruhn et al. identified five different 3′-UTR length variants in the ABCB1 gene, of which only the three longer fragments harbored miRNA binding sites [85], and Pereira et al. working on the transcription factor Nurr1 (NR4A2), from the superfamily of nuclear receptors identified a number of 3′UTR length variants in the rat Nurr1 mRNA and described the selective interaction of miR-93, miR-204 and miR-302d with the longest Nurr1 mRNA [86]. Lastly, we have recently shown that a splicing event at an internal/cryptic splice site of the murine Cd34 gene would regulate the differential accession of miRNA-125/351 to the 3′UTR or the CDS of the Cd34mRNA [87] (Fig. 2).

Fig. 2
figure2

Impact of alternatively expressed 3′UTRs on their interaction with miRNAs. Shown are changes in the structure of the 3′UTRs with the potential to impact on the binding of specific miRNAs. 1. The existence of alternative polyadenylation signals originate 3′UTRs of different lengths and different potential for miRNA binding. 2. Alternative exons encoding different 3′UTRs differ in their potential for miRNA binding. 3. Exonic switch. In the case of the Cd34 gene, an internal cryptic splice site (CSS) activates two different stop codons and generates two different exons 8, with the consequence that in one Cd34 isoform the binding site for a number of miRNAs is located in the 3′UTR, while in the other isoform it is located inside the CDS (taken from [87])

MicroRNAs in ATH progression

There is already a corpus of literature on the genetics and epigenetics of ATH evolution (see [40, 88, 89] for recent reviews), so that here in this section and in the next sections we will review recent developments on the relationship among miRNAs and ATH onset and progression and will highlight their use as therapeutic tools. In this sense, there are sound evidences demonstrating the involvement of miRNAs in many of the pathological processes that occur in ATH, and hundreds of miRNAs have been reported as key regulators of lipid handling, inflammation and cellular behaviors such as proliferation, migration and phenotypic switch [90], with alterations in the expression of miRNAs being detected not only in primary tissues but also in serum [91], urine [92], and exosomes [93]. Many reports have been published assessing modulation of miRNA expression in human patients and in mice models of ATH, some of them described in relatively mechanistic depth [94]. Table 2 reports recent descriptions of ATH-associated miRNAs either in animal models or in samples from human patients, their mRNA targets validated by luciferase reporter assays (not from bioinformatics predictions) and the effects of their expression alterations on ATH progression. This highlights the complexity of the miRNA/mRNA system, with different miRNAs targeting the same mRNA (e.g. miR-103 and miR-647 vs. PTEN), and a single miRNA targeting different mRNAs with different phenotypic outputs (miR-370 vs. FOXO1 and TLR4).

Table 2 ATH-associated miRNAs, mRNA targets and the effects of their expression on ATH progression

Small RNAs in gene-silencing therapies

Recent years have seen a trend to develop gene-silencing, small-RNA-based, therapies to specifically target mRNAs or other miRNAs [115, 116], an approach well-suited to target undruggable targets or polygenic pathologies given the ability of small-RNAs to target multiple mRNAs and pathways [117]. The list of miRNA-based, gene silencing (or mimicking) tools is growing and includes agomirs or single-stranded miRNAs (ss-miRNAs) and antagomirs (oligonucleotides containing the complementary sequences of the target miRNA), double-stranded small-interference RNAs (ds-siRNAs), or miRNA sponges ([118] and see next section). With a growing number of possible siRNA targets in ATH research [119], several other RNA-therapies are currently in clinical trials [120]. Thus, the first siRNA-based drug (Patisiran) has recently obtained the FDA approval to silence the transthyretin (TTR) mRNA (via RNA-interference by binding its 3′UTR) which caused a rare transthyretin-mediated amyloidosis polyneuropathy originated by the deposit of TTR-protein in tissues [121]. Other miRNA-candidates for medical intervention are currently in clinical development or in phase 1 or phase 2 clinical trials, such as MRG-110, a locked nucleic acid (LNA)-modified antisense oligonucleotide against miR-92 with a potential clinical application in wound healing and heart failure [122], a miR-29b mimic (Remlarsen) to prevent formation of fibrotic scars or cutaneous fibrosis [123], or anti-miR-21 oligonucleotides, which were seen to alleviate kidney disease in a murine model of Alport nephropathy [124]. On the other hand, miRNA-mimics or antagomirs have been also used at the laboratory level to modulate miRNA expression in ATH research [125], and recently therapies directed against miR-449a [126], miR-23a-5p [109], or miRNA-98 [112], among others, have been tried in animal models with encouraging results. Lastly, therapeutic miRNAs are not restricted to targeting specific mRNAs or miRNAs, and have been also used as co-factors to limit drug resistance through silencing of key proteins promoting low drug bioavailability [127].

Nevertheless, the use of miRNAs in gene-silencing (or gene-mimicking) therapies has yet to overcome a number of difficult issues such as developing efficient delivery vehicles, reducing unwanted off-target, side effects, or blocking immune activation. Without the aim of being exhaustive (see [128,129,130] for recent reviews on the topic), here we will cite some of the main drawbacks associated to the design of miRNA/siRNA delivering vehicles, such as the limitation in the amount of loaded siRNA due to the rigidity of ds-siRNAs and the low surface charge of individual siRNAs that make encapsulation challenging [131]. Furthermore, conventional complexation or encapsulation with lipids nanoparticles, cationic complexes, inorganic nanoparticles, RNA nanoparticles and dendrimers introduce a significant amount of vehicle which can lead to greater potential for immunogenic response or toxicity [132]. A plausible alternative is the systemic delivery with injections or intravenous administration, since injections of miRNA drug directly into the pathogenic site have been seen to enhance target specificity, efficacy and to minimize side effects [133]. In this sense, a number of chemical modifications, e.g. with phosphorothioate, 2′-O-methyl-phosphorothioate, N,N′-diethyl-4-(4-nitronaphthalen-1-ylazo)-phenylamine or the LNA-nilation (locked nucleic acid) have been seen to increase stability of the DNA/RNA moiety [134]. Lastly, new strategies are being pursuit to facilitate specific delivery of the miRNA/siRNA cargo, such as the addition of targeting moieties (specific antibodies) against a protein from target cells linked to the delivery vehicle to enhance its therapeutic efficacy [135], or the “TargomiRs”, mimicking miRNAs delivered by targeted bacterial minicells [136].

On the other hand, miRNA/siRNA therapies also have the potential for silencing off-target genes, causing unexpected adverse effects due to partial sequence complementarity to 3′UTRs, this meaning a significant obstacle to the therapeutic application of miRNAs [137]. In this sense, we have recently reported that systemic treatment with an anti-CD40-siRNA increased renal NF-kB activation in the ApoE-deficient mice model of ATH (Hueso et al., J. Inflammation, in the press). Furthermore, a phase 1 trial with an anti-tumour miRNA-34 mimic (MRX34) was stopped in 2016 after severe adverse events were reported in five patients who experienced a serious immune response [116], and another phase 1 trial on patients with malignant pleural mesothelioma, treated with a TargomiRs loaded with miR-16 and targeted to EGFR, reported infusion-related inflammatory symptoms and cardiac events [138], indicating the need for more research on the impact of carriers, vehicles and therapeutic nucleic acids on the inflammatory response.

Long non-coding RNAs (lncRNAs) and their functional relationship with miRNAs

LncRNAs and miRNA sponges

Long non-coding RNAs (lncRNAs) represent a heterogeneous class of non-coding RNAs that includes transcripts > 200 nucleotides, which lack functional protein coding ability but modulate gene expression through multiple distinct mechanisms at epigenetic, transcriptional or post-transcriptional levels [139]. LncRNAs coordinate and integrate multiple signaling pathways and have important roles in development, differentiation, and disease [140,141,142,143]. Currently estimated at more than 56,000 [144], the number of lncRNA genes more than doubles the number of protein-coding genes in the human genome, although due their low expression levels, many lncRNAs remain poorly characterized and annotated [145], so that it is likely that this number will be increased in the years to come. Based on their presumed function lncRNAs have been classified in a number of functional groups: competitive endogenous lncRNAs (ceRNAs) and circular lncRNAs (circRNAs), with potential roles as miRNA inhibitors [146, 147], enhancer-related RNAs (eRNAs), involved in transcriptional regulation [148], transcribed ultraconserved RNAs (T-UCRs), transcribed from non-coding highly conserved genomic regions [149], and the highly heterogeneous natural antisense transcripts (NATs), intronic lncRNAS and long intergenic RNAs (lincRNAs) among others, although this classification is neither exhaustive (see [150] for a recent and comprehensive review on the topic) nor unambiguous since a lncRNA could easily fit into more than one group [151].

We are especially interested in the lncRNAs that interact with miRNAs and function as competitive inhibitors of miRNA action (“sponges”), creating loss-of-function miRNA phenotypes and causing the de-repression of its targets [152, 153]. In the next sections we will give an overview of the role of these transcripts in the regulation of miRNA function, and when data are available in ATH progression.

LncRNAs in ATH progression and therapy: the case for ANRIL

High-throughput sequencing has allowed an exponential growth in the amount of sequence data generated in large number of individuals, and expanded the number of non-coding RNA (ncRNA) transcripts predicted to play a critical role in the pathogenesis of ATH [4] (Table 3), although because of their low expression levels, the study of lncRNAs is actually so challenging that many of them still remain poorly characterized and annotated. The lncRNA more clearly associated to ATH pathogenesis is CDKN2B-AS1, also known as ANRIL (Antisense Non-coding RNA in the INK4 locus) (see [1] for a recent review), that it is transcribed from chromosome 9p21 and acts as a lncRNA-guide to localize the polycomb repressive complex (PRC) at target promotors through a direct interaction with its subunits CBX7 or SUZ12 [154]. ANRIL is induced by the activation of the NF-kB pathway, and up-regulated ANRIL forms a functional complex with transcriptional factor Yin Yang 1 (YY1) to exert transcriptional regulation on inflammatory genes IL6 and IL8 in endothelial cells, while knockdown of ANRIL was seen to inhibit TNFα-induced expression of IL6 and IL8 expression [155], thus highlighting the involvement of ANRIL in the TNFα/NF-kB signalling that regulate inflammatory response. ANRIL expression was seen to be also correlated with a proliferative phenotype in vascular smooth muscle cells (VSMC) [156] and to act in trans, via Alu repetitive elements, to regulate other genes that participate in proatherogenic pathways [157]. Lastly, it has been reported a role for ANRIL as miRNA sponge in different tumours, such as miR-199a in triple-negative breast cancer [158], miR-186 in cervical cancer [159], or miR-323 in pediatric medulloblastoma [160].

Table 3 lncRNA:miRNA:mRNA axis in atherosclerosis progression

Competitive endogenous lncRNAs (ceRNAs) and circular lncRNAs (circRNAs)

Competing endogenous RNAs (ceRNAs) and circular lncRNAs (circRNAs) could be described as the “professional” miRNA “inhibitors/sponges”, i.e. the families of lncRNAs that work as “dominant negatives” of miRNA action by interacting with their seed regions to potentially block whole families of related miRNAs [152, 177]. This interaction cause the de-repression of their downstream targets, because miRNA-target interaction is strongly concentration-dependent [178], and has been seen to be de-regulated in a number of pathological conditions, from cancer to neurodegenerative diseases [179, 180]. CircRNAs are generated, by the thousands, from exonic or intronic regions in mammalian cells by a back-splicing event that links covalently the 3′ and 5′ ends of the transcript, so that they do not have a 5′ cap or 3′ tail [181, 182], and their expression is submitted to tissue/developmental-stage-regulation [183]. In recent years a number of groups have reported on the impact of lncRNA-sponges on ATH and related cardiovascular conditions with a mechanistic detail that include co-regulated miRNA and mRNA targets [184,185,186], and this is becoming a hot topic in cardiovascular research (see Table 3).

Transcribed ultraconserved RNAs (T-UCRs)

The first T-UCR RNA to be described was Evf-2, transcribed from the ultraconserved region between the homedomain containing genes Dlx-5 and Dlx-6. At the functional level, Efv-2 works as a coactivator of Dlx-2 to increase the activity of the transcriptional enhancer close to the Dlx-5/6 cluster [187]. Expression of T-URCs is tightly regulated, and a number of them (Uc.160+, Uc283+A and Uc.346+, Uc for Ultra Conserved) were seen to be silenced through DNA methylation at specific CpG islands in transformed cells [188]. Other disease associated T-UCRs have been detected, mainly in tumours, thus Uc.416+A was seen to be upregulated in renal cell carcinoma [189], as Uc.383 in hepatocellular carcinoma [190], Uc.338 in colorectal cancer [191], or Uc.63 in breast cancer ([192], see also [149] for a recent review). Interestingly, a number of authors have reported regulatory interactions among T-UCRs and miRNAs. In this sense, it was seminal the report of a direct interaction of Uc.283+A with pri-miR-195 that prevented the cleavage of this last by Drosha and hindered its maturation [193]. Subsequently, other authors have described further T-UCR/miRNA interactions such as that of Uc.173 with miRNA-195 [194] or miR-29b [195] to facilitate function of the intestinal epithelium, or the interaction of Uc.416+A with miR-153 in renal cell carcinoma [189].

Natural antisense transcripts (NATs)

NATs is a highly heterogeneous group of lncRNAs, transcribed from the complementary chain of target genes in an antisense orientation, that regulate post-transcriptionally gene expression via RNA:RNA interactions with mRNA or miRNAs [196]. In this sense, oncogenic lncRNA FOXD1-AS1 (FOXD1-antisense 1), the antisense transcript of the gene FOXD1, was reported to interact with miR339-5p and miR342-3p [197], tumor suppressor TP73-AS1 sponged miR-941 [198], while TSPAN31, the natural antisense transcript of cyclin dependent kinase 4 (CDK4), interacted with miR-135b in hepatocellular carcinoma causing TSPAN31 silencing and the subsequent upregulation of CDK4 [199].

Retrogressed genomic elements: processed pseudogenes and Alu repeated elements

Retrogressed genomic elements conform an heterogeneous group of expressed mRNAs that have made their way back into the genome through retrogression, i.e. a cycle of retrotranscription (mRNA to cDNA), and insertion (cDNA into genomic DNA) catalysed by the reverse transcriptase and endonuclease activities of the LINE retrotransposons [200]. Among them the best characterized are the processed pseudogenes, originated by the retrogression of a functional mRNA, and the repeated sequences of the Alu family, a member of the Short Interspersed Nuclear Elements (SINEs) group that come from a founder Alu element.

Processed pseudogenes underwent 3′-end polyadenylation and do not contain introns, since they come from fully-spliced transcripts, are flanked by duplicated integration sites 5 to 20 bp in length and upon genomic integration they suffer a process of sequence degeneration [201]. Pseudogenes were initially considered as the paradigm for “junk DNA” since these were genes (mRNAs) that lost its coding function, but recent works have re-evaluated their function and now it is widely accepted that they have a role in the regulation of gene expression and that its dysregulation is often associated with various human diseases including cancer [202]. According to last estimates, the number of processed pseudogenes in the human genome is similar to that of “true” coding genes [201], and some of them have been seen to function as miRNA sponges [203]. Although expressed pseudogenes could be considered as the perfect miRNA sponges since they provide mostly homologous miRNA binding sites in the correct sequence context, leading to the paradox that expression of the pseudogene could regulate expression of its corresponding gene [204], there are several constraints that could impact on the role of pseudogenes in miRNA function. Thus, the sequence degeneration subsequent to the integration of pseudogenes in the genome might inactivate miRNA binding sites, while the genomic context of the integration site could impose patterns of expression different from those of the parental gene. Nevertheless, the most critical factor is the difference in gene-number among the parental gene and its pseudogene progeny since not all genes have their corresponding expressed pseudogenes while a number of them are overrepresented in the pseudogene count, as the 2090 pseudogenes found for the 79 genes encoding human ribosomal proteins, from which 145 pseudogenes correspond to the RPL21 [205]. Despite these constraints, several groups have characterized different pseudogenes as miRNA sponges, and a manually curated database (miRsponge) has been created [203]. Thus PMS1 Homolog 2, Mismatch Repair System Component Pseudogene 2 (PMS2L2) has been described as a molecular sponge of miR-203 in osteoarthritis, with MCL-1 mRNA being the direct target of miR-203 [206], ferritin heavy chain 1 pseudogene 3 (FTH1P3) was shown to suppress miR-206 activity to promote ABCB1 (ATP binding cassette subfamily B member 1) protein expression [207], and to sponge miR-224-5p to modulate expression of fizzled 5 [208]. Furthermore, OCT4-pseudogene 4 was shown to protect OCT4 mRNA from miR-145 [209], and PTENp1 (PTEN pseudogene 1) was seen to shield PTEN mRNAs from miR-21 in oral squamous cell carcinoma (OSCC) [210], and from miR-106b and miR-93 in gastric tumours [211].

On the other hand, the other group of RNA dark transcripts that are also retrogressed to the genome and function as miRNA sponges is that of Short Interspersed Nuclear Elements (SINEs) [212]. SINEs include the Alu repeated sequences, a family of highly successful genomic parasites that have colonised the human genome to the extent that over 10% of it (i.e. one million copies) is composed by Alu-derived sequences (see [1] for a recent review). Alu repeats incorporated to the human genome from a founder element by using the reverse transcriptase encoded in LINEs [213, 214], and have subsequently undergone a process of sequence degeneration that has inactivated their transpositional ability, leaving only a few active members in the genome [215]. Genomic Alu elements include a RNA polymerase III internal promoter at the 5′ end of left arm and a short poly-A tail at the 3′ end of the right arm [216]. Although most of the members of the Alu family are silenced in the human genome, some of them are transcribed by RNA polymerase III into free Alu RNAs, as concatemers of individual Alu-RNAs by a yet unknown mechanism, or by RNA pol-II as mRNA-embedded Alus [216, 217], this last being a significant source of expressed Alu elements since aprox. 30% of human genes harbour a copy of an Alu repeat, usually at their 5′ or 3′ UTRs [218] (Fig. 3).

Fig. 3
figure3

Role of Alu elements in the regulation of miRNA activity. Shown are nuclear Alu elements transcribed from its own RNA pol III promoter in the case of being independent transcriptional units (left), or from an RNA pol II promoter in the case of being integrated inside another gene. In both cases these can behave as miRNA sponges by interacting with miRNAs. Some individual Alu elements can retroinsert into intergenic regions or inside other transcriptional units (taken from [1])

Although the functional relationships among Alu elements and miRNAs are complex and poorly understood, mostly due to the dual nature of Alu repeats as free transcripts or mRNA-inserted sequences, it is evident that the presence of the highly homologous, Alu repetitive sequences in different mRNAs could supply a platform of common binding sites for their coordinated targeting by miRNAs or to act as miRNA sponges [219]. In this sense, it has been reported a subset of 3′UTRs which included Alu elements with strong potential target sites for over 50 different miRNAs [220], and a group of 30 miRNAs that showed short-seed homology with highly conserved Alu elements at the 3′ UTRs of human mRNAs [221]. Furthermore, miR-15a-3p and miR-302d-3p, were recently shown to target RAD1, GTSE1, NR2C1, FKBP9 and UBE2I exclusively within Alu elements [222], while miR-661 caused the downregulation of Mdm2 and Mdm4 by interacting with Alu elements in their sequence [223], and Di Ruocco et al. described an Alu RNA that functioned as a miR-566 sponge [224].

Unveiling RNA: RNA regulatory networks in the progression of atherosclerosis

Establishing RNA:RNA regulatory networks that included mRNAs and miRNAs (and lncRNAs) would facilitate our ability to use them for research and therapeutic purposes. In this context, we could consider the miRNAome as a “safety net” to preserve homeostatic levels of mRNA expression, while lncRNA sponges would contribute to maintain regulatory levels of miRNAs. In any case, mRNAs, miRNAs and sponging lncRNAs conform RNA:RNA regulatory networks that are based on their direct physical interaction, which in turn depends on the sequence homology.

The first requisite for constructing a regulatory network is to identify the mRNA targets of a specific miRNA (or miRNA signature), and the most direct way to study these direct interactions is by isolating hybrid duplexes. A number of methods have been designed for this purpose, most of them variations of a basic miRNA/target cross-linking and immunoprecipitation (CLIP) assay followed by sequencing, such as HITS-CLIP [225], miR-CLIP [226], AGO-RIP-Seq [227], LIGR-Seq [228], Biotin-Pulldown and RNA-seq [229] etc. (see [230] for a recent review on the topic). Once miRNA/mRNA pairs have been identified with any of the above methods, the interaction is then confirmed by a luciferase assay in which the 3′UTR of the mRNA to test is cloned downstream a luciferase gene and the silencing ability of the miRNA is measured as changes in the light emitted by the construct [231]. Nevertheless, all these methods are complex, cumbersome and time-consuming, and are poorly suited for the clinical laboratory, so most of the miRNA work is currently performed by using bioinformatic algorithms that define miRNA/mRNA interactions (and predicts miRNA targets) after measuring sequential, structural or thermodynamic features (see [232] for a comprehensive review on the topic). Recent years have seen the proliferation of algorithms and web servers designed to predict miRNA targets [233], of which a few have established themselves as reference tools ([234] and see Table 4). Although it is not the aim of this review to make a comparative analysis of these algorithms (see [235] for a recent review on this topic), it is widely accepted that their predictions are frequently inconsistent, inaccurate and plenty of false positives [236, 237]. One answer to this problem has been the development of secondary algorithms that perform a more comprehensive analysis by combining the outputs of a number of primary target predictions (e.g. miRSystem combines seven primary algorithms while miRWalk2.0 combines 12 of them) and allow to control the stringency of the search by setting the number of common hits required for a prediction to be considered as positive [238, 239], but the output of these analysis also are long lists of predicted targets. The answer to overcome these problems has been the development of integrated/enrichment analysis which are well suited to deal with long lists of genes, though the results obtained are not so solid as those from experimental assays. In the integrated analysis, the list of predicted targets is pruned by establishing additional conditions to confirm targets [240, 241]. Although there are different approaches depending on the kind of sequence information available, a typical experiment would compare the entire list of predicted targets for a single miRNA or a miRNA signature with a list of Differentially Expressed Genes (DEGs) from the same experimental background or from an expression repository such as the Gene Expression Omnibus (GEO) [242], and the entries common to both lists would be saved. In a second step, those showing a counter-regulated expression vs. the miRNA/s (i.e. inversely correlated expression levels) would integrate a restricted list of preferential putative targets (Table 4 shows different algorithms for integrative analysis). By using a similar approach, Zhang et al. have recently constructed a miRNA:mRNA regulatory network for ATH progression in icariin-treated, high-fat fed ApoE-deficient mice which showed that changes in miRNA expression mainly affected the PI3K/Akt, Ras, ErbB and VEGF signalling pathways in lesions [243].

Table 4 Resources for miRNA research

The process of delineating RNA regulatory networks has been further facilitated by the development of the Gene Ontology (GO) enrichment analysis in which individual genes from a set of Differentially Expressed Genes (DEGs) from a stated condition are classified in pre-defined categories (GO-terms) to identify those that account for more DEGs (enrichment) [244]. These will define gene networks as structural pathways or molecular functions specific for that condition. GO analysis on ATH-DEGs has showed an enrichment in proteins related to nucleic acid function, such as epigenetic regulators [245], [liver X] nuclear receptors [246], or ribosomal proteins [247], while our own GO analysis on a subset of miRNA targets obtained after an integrated analysis in ATH also showed an enrichment in genes related to the function of nucleic acids (Hueso et al., manuscript in preparation).

Lastly, inclusion of lncRNAs in the efforts to delineate disease-related regulatory networks greatly increases their complexity, not only because this means the inclusion of new players in the game but also because lncRNAs are very heterogeneous in function and can act at different levels as miRNA sponges, compete with miRNAs for shared mRNA targets, or interact with the chromatin structure, facts that greatly hinder their functional characterization. Furthermore, information on the function of individual lncRNAs is scant and incomplete for most of them, since only a few hundreds of lncRNAs have been yet functionally characterized, and for most of them the detailed mechanisms of action are still to be determined. Nevertheless, a number of groups have reported mutual miRNA:mRNA:lncRNA interactions in the context of ATHp ([248, 249] and see Table 3).

The dark transcriptome in clinics: future challenges

One of the most striking consequences of the completion of the human genome has been the conversion of the dark transcriptome (encoded by the “junk” DNA) into an elaborated catalogue of regulatory RNAs, many of them related to the onset and progression of human diseases. In this sense, the next challenge is to make profit of this ncRNA revolution in the clinical context to explore their role as specific biomarkers or as etiopathogenic intermediates, but this will require new technical developments on the way that sequencing information is generated, managed and interpreted.

For many years, the mantra of the sequencing industry has been “faster, longer and cheaper”, and it is likely that this will be also the aim for the development of the next generation of sequencing machines with the addendum of giving extra importance to accuracy. Sequencing ncRNAs up to clinical analytical standards is not an easy business since it requires an unprecedented degree of accuracy and flexibility. Accuracy because detecting point mutations in ncRNAs (critical for cancer research) cannot be compromised by the technical noise from the reagents used for amplifying and generating the sequence or from the machine used to detect it [268], and performing multiplex sequencing in a sample is not the solution since this significantly increases the costs associated to the process. Flexibility, because ncRNAs are very heterogeneous in size and structure, with many events of alternative splicing that originate multiple, partially homologous, forms that suppose a challenge to reconstruct long sequences from short reads. Sequencing genomic regions rich in clustered repetitive sequences (e.g. Alu repeats) pose a similar problem that can only be solved by increasing the length of the sequence reads without compromising accuracy. Nevertheless, the sequencing industry has demonstrated to be innovative and dynamic, and although at this time it is difficult to ascertain which of the sequencing platforms currently in use will rule in the next future, whether different platforms will specialize in specific niches, or if there’s yet to come a new and disruptive technology, we can give for sure that this problem is being addressed.

The second big challenge to introduce ncRNA expression profiling in the clinical context has to be with the way that the sequencing information generated is managed and used. On the one hand, all this information has to be stored in a way that can be easily retrieved, and new software has to be developed to extract biological or medical “sense” from it. Furthermore, the problem of data compatibility and standardization is always behind the door. With many different sequencing platforms in the market (and other many to come in the future) developers should make an effort to share standards and avoid proprietary data formats, to encourage data sharing and to provide public, non-commercial and unrestricted access to data. Failure on doing this will lead us to a nightmare of data islands. On the other hand, data interpretation at the whole genome/transcriptome level will surely require using artificial intelligence and deep learning algorithms for the analysis and to discover new biological insights from sequencing data. Genomic datasets are too large and complex to be mined by individual researchers looking for pairwise correlations, so that the need for new and potent analytical tools is clear. Machine learning and deep learning, a subdiscipline of machine learning, are powerful tools suited to data-driven sciences that are currently used to automatically explore the genome and detect patterns in data that could be used to unravel novel properties of noncoding regions and to understand how they impact in human health [269, 270]. The strong flexibility and high accuracy of deep learning methods is supported by the successive introduction of a variety of deep architectures that are superior over other existing methods. In this sense, Splice AI, a deep neural network, has been used to predict splice junctions from a pre-mRNA transcript, as well as noncoding variants with the ability to cause cryptic splicing events [271]. It is likely that many other similar algorithms will be developed to assist the analysis of whole transcriptomes/genomes.

Conclusions

We are on the verge of a new revolution in the way we see disease and the normal, non-diseased state. For many years, diseases have been linked to mutations in the genomic DNA or to alterations in the expression of coding mRNAs. We now know that this “coding world” is just the tip of the gene expression iceberg. It is not only that there are more non-coding RNAs than coding ones, but that all these RNAs interact among them (and with chromatin), to create complex regulatory miRNA/lncRNA/mRNA networks whose unbalance underlies the basis of complex diseases. Constructing accurate models of disease, a requisite for developing new and personalized treatments, will require new developments to generate accurate sequencing information as well as to make this information manageable and available to all ranks involved in alleviating the burden associated to human diseases.

Availability of data and materials

Not applicable.

Abbreviations

ATH:

atherosclerosis

ceRNAs:

competing endogenous RNAs

circRNAs:

circular RNAs

DEGs:

Differentially Expressed Genes

EST:

expressed sequence tag

LINEs:

long interspersed nuclear element

lncRNAs:

long non-coding RNAs

miRNAs:

microRNAs

ncRNAs:

non-coding RNAs

NGS:

next generation sequencing

SINEs:

short interspersed nuclear element

3′UTR:

3′ untranslated region

References

  1. 1.

    Hueso M et al (2018) ALUminating the path of atherosclerosis progression: chaos theory suggests a role for Alu repeats in the development of atherosclerotic vascular disease. Int J Mol Sci 19(6):1734

  2. 2.

    Torres N et al (2015) Nutrition and atherosclerosis. Arch Med Res 46(5):408–426

  3. 3.

    Nahrendorf M, Swirski FK (2015) Lifestyle effects on hematopoiesis and atherosclerosis. Circ Res 116(5):884–894

  4. 4.

    Turner AW et al (2019) Multi-omics approaches to study long non-coding RNA function in atherosclerosis. Front Cardiovasc Med 6:9

  5. 5.

    Marian AJ (2012) The enigma of genetics etiology of atherosclerosis in the post-GWAS era. Curr Atheroscler Rep 14(4):295–299

  6. 6.

    Koenig W (2013) High-sensitivity C-reactive protein and atherosclerotic disease: from improved risk prediction to risk-guided therapy. Int J Cardiol 168(6):5126–5134

  7. 7.

    Vitali C, Khetarpal SA, Rader DJ (2017) HDL cholesterol metabolism and the risk of CHD: new insights from human genetics. Curr Cardiol Rep 19(12):132

  8. 8.

    Dron JS, Hegele RA (2017) Genetics of triglycerides and the risk of atherosclerosis. Curr Atheroscler Rep 19(7):31

  9. 9.

    Dron JS, Ho R, Hegele RA (2017) Recent advances in the genetics of atherothrombotic disease and its determinants. Arterioscler Thromb Vasc Biol 37(10):e158–e166

  10. 10.

    Tabaei S, Tabaee SS (2019) DNA methylation abnormalities in atherosclerosis. Artif Cells Nanomed Biotechnol 47(1):2031–2041

  11. 11.

    Aavik E, Babu M, Yla-Herttuala S (2019) DNA methylation processes in atheosclerotic plaque. Atherosclerosis 281:168–179

  12. 12.

    Chen HH, Stewart AF (2016) Transcriptomic signature of atherosclerosis in the peripheral blood: fact or fiction? Curr Atheroscler Rep 18(12):77

  13. 13.

    Fan J et al (2018) Genomic and transcriptomic analysis of hypercholesterolemic rabbits: progress and perspectives. Int J Mol Sci 19(11):3512

  14. 14.

    Consortium, E.P. (2012) An integrated encyclopedia of DNA elements in the human genome. Nature 489(7414):57–74

  15. 15.

    Thurman RE et al (2012) The accessible chromatin landscape of the human genome. Nature 489(7414):75–82

  16. 16.

    Neph S et al (2012) An expansive human regulatory lexicon encoded in transcription factor footprints. Nature 489(7414):83–90

  17. 17.

    Gerstein MB et al (2012) Architecture of the human regulatory network derived from ENCODE data. Nature 489(7414):91–100

  18. 18.

    Litman T, Stein WD (2019) Obtaining estimates for the ages of all the protein-coding genes and most of the ontology-identified noncoding genes of the human genome, assigned to 19 phylostrata. Semin Oncol 46(1):3–9

  19. 19.

    Pertea M et al (2018) CHESS: a new human gene catalog curated from thousands of large-scale RNA sequencing experiments reveals extensive transcriptional noise. Genome Biol 19(1):208

  20. 20.

    Uszczynska-Ratajczak B et al (2018) Towards a complete map of the human long non-coding RNA transcriptome. Nat Rev Genet 19(9):535–548

  21. 21.

    Palazzo AF, Lee ES (2015) Non-coding RNA: what is functional and what is junk? Front Genet 6:2

  22. 22.

    Johnson JM et al (2005) Dark matter in the genome: evidence of widespread transcription detected by microarray tiling experiments. Trends Genet 21(2):93–102

  23. 23.

    Pennisi E (2010) Shining a light on the genome’s ‘dark matter’. Science 330(6011):1614

  24. 24.

    Kirk JM et al (2018) Functional classification of long non-coding RNAs by k-mer content. Nat Genet 50(10):1474–1482

  25. 25.

    Ma L, Bajic VB, Zhang Z (2013) On the classification of long non-coding RNAs. RNA Biol 10(6):925–933

  26. 26.

    Siomi MC et al (2011) PIWI-interacting small RNAs: the vanguard of genome defence. Nat Rev Mol Cell Biol 12(4):246–258

  27. 27.

    Hombach S, Kretz M (2016) Non-coding RNAs: classification, biology and functioning. Adv Exp Med Biol 937:3–17

  28. 28.

    Costa FF (2010) Non-coding RNAs: meet thy masters. BioEssays 32(7):599–608

  29. 29.

    Wright MW, Bruford EA (2011) Naming ‘junk’: human non-protein coding RNA (ncRNA) gene nomenclature. Hum Genomics 5(2):90–98

  30. 30.

    Dey BK, Mueller AC, Dutta A (2014) Long non-coding RNAs as emerging regulators of differentiation, development, and disease. Transcription 5(4):e944014

  31. 31.

    Prasanth KV, Spector DL (2007) Eukaryotic regulatory RNAs: an answer to the ‘genome complexity’ conundrum. Genes Dev 21(1):11–42

  32. 32.

    Waller P, Blann AD (2019) Non-coding RNAs—a primer for the laboratory scientist. Br J Biomed Sci 76:157–165

  33. 33.

    Consortium, E.P. et al (2007) Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature 447(7146):799–816

  34. 34.

    Carninci P, Yasuda J, Hayashizaki Y (2008) Multifaceted mammalian transcriptome. Curr Opin Cell Biol 20(3):274–280

  35. 35.

    van Bakel H et al (2010) Most “dark matter” transcripts are associated with known genes. PLoS Biol 8(5):e1000371

  36. 36.

    Ponting CP, Belgard TG (2010) Transcribed dark matter: meaning or myth? Hum Mol Genet 19(R2):R162–R168

  37. 37.

    Nagano T, Fraser P (2011) No-nonsense functions for long noncoding RNAs. Cell 145(2):178–181

  38. 38.

    Crick FH (1958) On protein synthesis. Symp Soc Exp Biol 12:138–163

  39. 39.

    Brenner S, Jacob F, Meselson M (1961) An unstable intermediate carrying information from genes to ribosomes for protein synthesis. Nature 190:576–581

  40. 40.

    Burke AC, Huff MW (2018) Regression of atherosclerosis: lessons learned from genetically modified mouse models. Curr Opin Lipidol 29(2):87–94

  41. 41.

    Sanger F, Nicklen S, Coulson AR (1977) DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci USA 74(12):5463–5467

  42. 42.

    Maxam AM, Gilbert W (1977) A new method for sequencing DNA. Proc Natl Acad Sci USA 74(2):560–564

  43. 43.

    Lander ES et al (2001) Initial sequencing and analysis of the human genome. Nature 409(6822):860–921

  44. 44.

    Venter JC et al (2001) The sequence of the human genome. Science 291(5507):1304–1351

  45. 45.

    Tang F et al (2009) mRNA-Seq whole-transcriptome analysis of a single cell. Nat Methods 6(5):377–382

  46. 46.

    Karsch-Mizrachi I et al (2018) The international nucleotide sequence database collaboration. Nucleic Acids Res 46(D1):D48–D51

  47. 47.

    O’Leary NA et al (2016) Reference sequence (RefSeq) database at NCBI: current status, taxonomic expansion, and functional annotation. Nucleic Acids Res 44(D1):D733–D745

  48. 48.

    Yandell M, Ence D (2012) A beginner’s guide to eukaryotic genome annotation. Nat Rev Genet 13(5):329–342

  49. 49.

    Cunningham F et al (2019) Ensembl 2019. Nucleic Acids Res 47(D1):D745–D751

  50. 50.

    Sayers EW et al (2019) Database resources of the National Center for Biotechnology Information. Nucleic Acids Res 47(D1):D23–D28

  51. 51.

    Sanger F, Coulson AR (1975) A rapid method for determining sequences in DNA by primed synthesis with DNA polymerase. J Mol Biol 94(3):441–448

  52. 52.

    Sanger F, Coulson AR (1978) The use of thin acrylamide gels for DNA sequencing. FEBS Lett 87(1):107–110

  53. 53.

    Prober JM et al (1987) A system for rapid DNA sequencing with fluorescent chain-terminating dideoxynucleotides. Science 238(4825):336–341

  54. 54.

    Ciora T, Denefle P, Mayaux JF (1991) Rapid one-step automated sequencing reactions for 16 DNA samples using Taq polymerase and fluorescent primers. Nucleic Acids Res 19(1):188

  55. 55.

    Rosenthal A, Charnock-Jones DS (1993) Linear amplification sequencing with dye terminators. Methods Mol Biol 23:281–296

  56. 56.

    Mardis ER (2006) Anticipating the 1,000 dollar genome. Genome Biol 7(7):112

  57. 57.

    Kono N, Arakawa K (2019) Nanopore sequencing: review of potential applications in functional genomics. Dev Growth Differ 61(5):316–326

  58. 58.

    Buermans HP, den Dunnen JT (2014) Next generation sequencing technology: advances and applications. Biochim Biophys Acta 1842(10):1932–1941

  59. 59.

    Ambros V (2001) microRNAs: tiny regulators with great potential. Cell 107(7):823–826

  60. 60.

    Souquere S et al (2010) Highly ordered spatial organization of the structural long noncoding NEAT1 RNAs within paraspeckle nuclear bodies. Mol Biol Cell 21(22):4020–4027

  61. 61.

    Adams MD et al (1991) Complementary DNA sequencing: expressed sequence tags and human genome project. Science 252(5013):1651–1656

  62. 62.

    Adams MD et al (1992) Sequence identification of 2,375 human brain genes. Nature 355(6361):632–634

  63. 63.

    Okubo K et al (1992) Large scale cDNA sequencing for analysis of quantitative and qualitative aspects of gene expression. Nat Genet 2(3):173–179

  64. 64.

    Takahashi N, Ko MS (1993) The short 3′-end region of complementary DNAs as PCR-based polymorphic markers for an expression map of the mouse genome. Genomics 16(1):161–168

  65. 65.

    Kotake Y et al (2011) Long non-coding RNA ANRIL is required for the PRC2 recruitment to and silencing of p15(INK4B) tumor suppressor gene. Oncogene 30(16):1956–1962

  66. 66.

    Burd CE et al (2010) Expression of linear and novel circular forms of an INK4/ARF-associated non-coding RNA correlates with atherosclerosis risk. PLoS Genet 6(12):e1001233

  67. 67.

    Sarkar D et al (2017) Multiple isoforms of ANRIL in melanoma cells: structural complexity suggests variations in processing. Int J Mol Sci 18(7):1378

  68. 68.

    Holdt LM, Teupser D (2018) Long noncoding RNA ANRIL: Lnc-ing genetic variation at the chromosome 9p21 locus to molecular mechanisms of atherosclerosis. Front Cardiovasc Med 5:145

  69. 69.

    Yeku O, Frohman MA (2011) Rapid amplification of cDNA ends (RACE). Methods Mol Biol 703:107–122

  70. 70.

    Eipper-Mains JE et al (2011) microRNA-Seq reveals cocaine-regulated expression of striatal microRNAs. RNA 17(8):1529–1543

  71. 71.

    Hafner M et al (2008) Identification of microRNAs and other small regulatory RNAs using cDNA library sequencing. Methods 44(1):3–12

  72. 72.

    Carthew RW, Sontheimer EJ (2009) Origins and mechanisms of miRNAs and siRNAs. Cell 136(4):642–655

  73. 73.

    Ha M, Kim VN (2014) Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol 15(8):509–524

  74. 74.

    Alles J et al (2019) An estimate of the total number of true human miRNAs. Nucleic Acids Res 47(7):3353–3364

  75. 75.

    Friedman RC et al (2009) Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 19(1):92–105

  76. 76.

    Sayed D, Abdellatif M (2011) MicroRNAs in development and disease. Physiol Rev 91(3):827–887

  77. 77.

    Lewis BP, Burge CB, Bartel DP (2005) Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120(1):15–20

  78. 78.

    Vidigal JA, Ventura A (2015) The biological functions of miRNAs: lessons from in vivo studies. Trends Cell Biol 25(3):137–147

  79. 79.

    Grassi E et al (2018) Choice of alternative polyadenylation sites, mediated by the RNA-binding protein Elavl3, plays a role in differentiation of inhibitory neuronal progenitors. Front Cell Neurosci 12:518

  80. 80.

    Chen LL (2016) Linking long noncoding RNA localization and function. Trends Biochem Sci 41(9):761–772

  81. 81.

    Liaw HH et al (2013) Differential microRNA regulation correlates with alternative polyadenylation pattern between breast cancer and normal cells. PLoS ONE 8(2):e56958

  82. 82.

    Ogorodnikov A, Kargapolova Y, Danckwardt S (2016) Processing and transcriptome expansion at the mRNA 3′ end in health and disease: finding the right end. Pflugers Arch 468(6):993–1012

  83. 83.

    Wanke KA, Devanna P, Vernes SC (2018) Understanding neurodevelopmental disorders: the promise of regulatory variation in the 3′UTRome. Biol Psychiatry 83(7):548–557

  84. 84.

    Xiao R et al (2019) Adipogenesis associated Mth938 domain containing (AAMDC) protein expression is regulated by alternative polyadenylation and microRNAs. FEBS Lett 593(14):1724–1734

  85. 85.

    Bruhn O et al (2016) Length variants of the ABCB1 3′-UTR and loss of miRNA binding sites: possible consequences in regulation and pharmacotherapy resistance. Pharmacogenomics 17(4):327–340

  86. 86.

    Pereira LA et al (2017) Long 3′UTR of Nurr1 mRNAs is targeted by miRNAs in mesencephalic dopamine neurons. PLoS ONE 12(11):e0188177

  87. 87.

    Hueso M et al (2019) An exonic switch regulates differential accession of microRNAs to the Cd34 transcript in atherosclerosis progression. Genes (Basel) 10(1):70

  88. 88.

    Xu S, Pelisek J, Jin ZG (2018) Atherosclerosis is an epigenetic disease. Trends Endocrinol Metab 29(11):739–742

  89. 89.

    Thomas MR, Lip GY (2017) Novel risk markers and risk assessments for cardiovascular disease. Circ Res 120(1):133–149

  90. 90.

    Hung J et al (2018) Targeting non-coding RNA in vascular biology and disease. Front Physiol 9:1655

  91. 91.

    MacLellan SA et al (2014) Pre-profiling factors influencing serum microRNA levels. BMC Clin Pathol 14:27

  92. 92.

    Papadopoulos T et al (2015) miRNAs in urine: a mirror image of kidney disease? Expert Rev Mol Diagn 15(3):361–374

  93. 93.

    Chevillet JR et al (2015) Quantitative and stoichiometric analysis of the microRNA content of exosomes. Proc Natl Acad Sci USA 111(41):14888–14893

  94. 94.

    Johnson JL (2019) Elucidating the contributory role of microRNA to cardiovascular diseases (a review). Vasc Pharmacol 114:31–48

  95. 95.

    Yao Y et al (2019) Platelet-derived exosomal MicroRNA-25-3p inhibits coronary vascular endothelial cell inflammation through Adam10 via the NF-kappaB signaling pathway in ApoE(-/-) mice. Front Immunol 10:2205

  96. 96.

    Yu DR et al (2020) MicroRNA-9 overexpression suppresses vulnerable atherosclerotic plaque and enhances vascular remodeling through negative regulation of the p38MAPK pathway via OLR1 in acute coronary syndrome. J Cell Biochem 121:49–62

  97. 97.

    Xu CX et al. (2019) MiR-647 promotes proliferation and migration of ox-LDL-treated vascular smooth muscle cells through regulating PTEN/PI3K/AKT pathway. Eur Rev Med Pharmacol Sci 23(16):7110–7119

  98. 98.

    Wu BW et al (2019) Downregulation of microRNA-135b promotes atherosclerotic plaque stabilization in atherosclerotic mice by upregulating erythropoietin receptor. IUBMB Life. https://doi.org/10.1002/iub.2155

  99. 99.

    Wu W et al (2019) Overexpression of miR-223 inhibits foam cell formation by inducing autophagy in vascular smooth muscle cells. Am J Transl Res 11(7):4326–4336

  100. 100.

    Zhou Z et al (2019) MicroRNA-30-3p suppresses inflammatory factor-induced endothelial cell injury by targeting TCF21. Mediators Inflamm 2019:1342190

  101. 101.

    Han Z et al (2019) MicroRNA-99a-5p alleviates atherosclerosis via regulating Homeobox A1. Life Sci 232:116664

  102. 102.

    Jiang L et al (2020) Inhibition of microRNA-103 attenuates inflammation and endoplasmic reticulum stress in atherosclerosis through disrupting the PTEN-mediated MAPK signaling. J Cell Physiol 235(1):380–393

  103. 103.

    Zhang W et al (2019) MicroRNA-451 inhibits vascular smooth muscle cell migration and intimal hyperplasia after vascular injury via Ywhaz/p38 MAPK pathway. Exp Cell Res 379(2):214–224

  104. 104.

    Yang L, Gao C (2019) MiR-590 inhibits endothelial cell apoptosis by inactivating the TLR4/NF-kappaB pathway in atherosclerosis. Yonsei Med J 60(3):298–307

  105. 105.

    Shi X, Chen X (2019) Effect of microRNA-370 on coronary atherosclerosis and its underlying mechanism. Exp Ther Med 17(1):115–122

  106. 106.

    Yin J, Hou X, Yang S (2019) microRNA-338-3p promotes ox-LDL-induced endothelial cell injury through targeting BAMBI and activating TGF-beta/Smad pathway. J Cell Physiol 234(7):11577–11586

  107. 107.

    Iaconetti C et al (2015) Down-regulation of miR-23b induces phenotypic switching of vascular smooth muscle cells in vitro and in vivo. Cardiovasc Res 107(4):522–533

  108. 108.

    Qu Y, Zhang N (2018) miR-365b-3p inhibits the cell proliferation and migration of human coronary artery smooth muscle cells by directly targeting ADAMTS1 in coronary atherosclerosis. Exp Ther Med 16(5):4239–4245

  109. 109.

    Yang S et al (2018) MicroRNA-23a-5p promotes atherosclerotic plaque progression and vulnerability by repressing ATP-binding cassette transporter A1/G1 in macrophages. J Mol Cell Cardiol 123:139–149

  110. 110.

    Qin B et al (2018) MicroRNA-142-3p induces atherosclerosis-associated endothelial cell apoptosis by directly targeting rictor. Cell Physiol Biochem 47(4):1589–1603

  111. 111.

    Su G et al (2018) Downregulation of miR-34a promotes endothelial cell growth and suppresses apoptosis in atherosclerosis by regulating Bcl-2. Heart Vessels 33(10):1185–1194

  112. 112.

    Dai Y et al (2018) MicroRNA-98 regulates foam cell formation and lipid accumulation through repression of LOX-1. Redox Biol 16:255–262

  113. 113.

    Yin D et al (2018) Pro-angiogenic role of LncRNA HULC in microvascular endothelial cells via sequestrating miR-124. Cell Physiol Biochem 50(6):2188–2202

  114. 114.

    Tian D et al (2018) MiR-370 inhibits vascular inflammation and oxidative stress triggered by oxidized low-density lipoprotein through targeting TLR4. J Cell Biochem 119(7):6231–6237

  115. 115.

    Ahmadzada T, Reid G, McKenzie DR (2018) Fundamentals of siRNA and miRNA therapeutics and a review of targeted nanoparticle delivery systems in breast cancer. Biophys Rev 10(1):69–86

  116. 116.

    Hanna J, Hossain GS, Kocerha J (2019) The potential for microRNA therapeutics and clinical research. Front Genet 10:478

  117. 117.

    Ozcan G et al (2015) Preclinical and clinical development of siRNA-based therapeutics. Adv Drug Deliv Rev 87:108–119

  118. 118.

    Bernardo BC et al (2015) miRNA therapeutics: a new class of drugs with potential therapeutic applications in the heart. Future Med Chem 7(13):1771–1792

  119. 119.

    Pradhan-Nabzdyk L et al (2014) Current siRNA targets in atherosclerosis and aortic aneurysm. Discov Med 17(95):233–246

  120. 120.

    Zhou LY et al (2019) Current RNA-based therapeutics in clinical trials. Curr Gene Ther 19(3):172–196

  121. 121.

    Hoy SM (2018) Patisiran: first global approval. Drugs 78(15):1625–1631

  122. 122.

    Gallant-Behm CL et al (2018) A synthetic microRNA-92a inhibitor (MRG-110) accelerates angiogenesis and wound healing in diabetic and nondiabetic wounds. Wound Repair Regen 26(4):311–323

  123. 123.

    Gallant-Behm CL et al (2019) A MicroRNA-29 Mimic (Remlarsen) represses extracellular matrix expression and fibroplasia in the skin. J Invest Dermatol 139(5):1073–1081

  124. 124.

    Gomez IG et al (2015) Anti-microRNA-21 oligonucleotides prevent Alport nephropathy progression by stimulating metabolic pathways. J Clin Invest 125(1):141–156

  125. 125.

    Loyer X et al (2015) MicroRNAs as therapeutic targets in atherosclerosis. Expert Opin Ther Targets 19(4):489–496

  126. 126.

    Jiang L et al (2019) miR-449a induces EndMT, promotes the development of atherosclerosis by targeting the interaction between AdipoR2 and E-cadherin in Lipid Rafts. Biomed Pharmacother 109:2293–2304

  127. 127.

    Guo J et al (2018) The miR 495-UBE2C-ABCG2/ERCC1 axis reverses cisplatin resistance by downregulating drug resistance genes in cisplatin-resistant non-small cell lung cancer cells. EBioMedicine 35:204–221

  128. 128.

    Kim B, Park JH, Sailor MJ (2019) Rekindling RNAi therapy: materials design requirements for in vivo siRNA delivery. Adv Mater 31:e1903637

  129. 129.

    Ickenstein LM, Garidel P (2019) Lipid-based nanoparticle formulations for small molecules and RNA drugs. Expert Opin Drug Deliv 16(11):1205–1226

  130. 130.

    Majumder J, Taratula O, Minko T (2019) Nanocarrier-based systems for targeted and site specific therapeutic delivery. Adv Drug Deliv Rev 144:57–77

  131. 131.

    Lee JB et al (2012) Self-assembled RNA interference microsponges for efficient siRNA delivery. Nat Mater 11(4):316–322

  132. 132.

    Islas JF, Moreno-Cuevas JE (2018) A MicroRNA perspective on cardiovascular development and diseases: an update. Int J Mol Sci 19(7):2075

  133. 133.

    Chen Y, Gao DY, Huang L (2015) In vivo delivery of miRNAs for cancer therapy: challenges and strategies. Adv Drug Deliv Rev 81:128–141

  134. 134.

    Kumar V et al (2018) Therapeutic potential of OMe-PS-miR-29b1 for treating liver fibrosis. Mol Ther 26(12):2798–2811

  135. 135.

    Wang Z et al (2019) Anti-GPC3 antibody tagged cationic switchable lipid-based nanoparticles for the Co-delivery of anti-miRNA27a and sorafenib in liver cancers. Pharm Res 36(10):145

  136. 136.

    Reid G et al (2016) Clinical development of TargomiRs, a miRNA mimic-based treatment for patients with recurrent thoracic cancer. Epigenomics 8(8):1079–1085

  137. 137.

    Jackson AL, Linsley PS (2010) Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nat Rev Drug Discov 9(1):57–67

  138. 138.

    van Zandwijk N et al (2017) Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study. Lancet Oncol 18(10):1386–1396

  139. 139.

    Bhat SA et al (2016) Long non-coding RNAs: mechanism of action and functional utility. Noncoding RNA Res 1(1):43–50

  140. 140.

    Grote P, Herrmann BG (2015) Long noncoding RNAs in organogenesis: making the difference. Trends Genet 31(6):329–335

  141. 141.

    Haemmerle M, Gutschner T (2015) Long non-coding RNAs in cancer and development: where do we go from here? Int J Mol Sci 16(1):1395–1405

  142. 142.

    Isin M, Dalay N (2015) LncRNAs and neoplasia. Clin Chim Acta 444:280–288

  143. 143.

    Rinn JL, Chang HY (2012) Genome regulation by long noncoding RNAs. Annu Rev Biochem 81:145–166

  144. 144.

    Xie C et al (2014) NONCODEv4: exploring the world of long non-coding RNA genes. Nucleic Acids Res 42(Database issue):D98–D103

  145. 145.

    Fok ET et al (2017) The emerging molecular biology toolbox for the study of long noncoding RNA biology. Epigenomics 9(10):1317–1327

  146. 146.

    Thomson DW, Dinger ME (2016) Endogenous microRNA sponges: evidence and controversy. Nat Rev Genet 17(5):272–283

  147. 147.

    Panda AC (2018) Circular RNAs act as miRNA sponges. Adv Exp Med Biol 1087:67–79

  148. 148.

    de Lara JC, Arzate-Mejia RG, Recillas-Targa F (2019) Enhancer RNAs: insights Into Their Biological Role. Epigenet Insights 12:2516865719846093

  149. 149.

    Terracciano D et al (2017) The role of a new class of long noncoding RNAs transcribed from ultraconserved regions in cancer. Biochim Biophys Acta Rev Cancer 1868(2):449–455

  150. 150.

    Jarroux J, Morillon A, Pinskaya M (2017) History, discovery, and classification of lncRNAs. Adv Exp Med Biol 1008:1–46

  151. 151.

    St Laurent G, Wahlestedt C, Kapranov P (2015) The Landscape of long noncoding RNA classification. Trends Genet 31(5):239–251

  152. 152.

    Ebert MS, Sharp PA (2010) Emerging roles for natural microRNA sponges. Curr Biol 20(19):R858–R861

  153. 153.

    Bak RO, Mikkelsen JG (2014) miRNA sponges: soaking up miRNAs for regulation of gene expression. Wiley Interdiscip Rev RNA 5(3):317–333

  154. 154.

    Meseure D et al (2016) Expression of ANRIL-polycomb complexes-CDKN2A/B/ARF genes in breast tumors: identification of a two-gene (EZH2/CBX7) signature with independent prognostic value. Mol Cancer Res 14(7):623–633

  155. 155.

    Zhou X et al (2016) Long non-coding RNA ANRIL regulates inflammatory responses as a novel component of NF-kappaB pathway. RNA Biol 13(1):98–108

  156. 156.

    Motterle A et al (2012) Functional analyses of coronary artery disease associated variation on chromosome 9p21 in vascular smooth muscle cells. Hum Mol Genet 21(18):4021–4029

  157. 157.

    Holdt LM et al (2013) Alu elements in ANRIL non-coding RNA at chromosome 9p21 modulate atherogenic cell functions through trans-regulation of gene networks. PLoS Genet 9(7):e1003588

  158. 158.

    Xu ST et al (2017) Long non-coding RNA ANRIL promotes carcinogenesis via sponging miR-199a in triple-negative breast cancer. Biomed Pharmacother 96:14–21

  159. 159.

    Zhang JJ et al (2018) Long noncoding RNA ANRIL promotes cervical cancer development by acting as a sponge of miR-186. Oncol Res 26(3):345–352

  160. 160.

    Zhang H, Wang X, Chen X (2017) Potential role of long non-coding RNA ANRIL in pediatric medulloblastoma through promotion on proliferation and migration by targeting miR-323. J Cell Biochem 118(12):4735–4744

  161. 161.

    Xiao X et al (2017) LncRNA MALAT1 sponges miR-204 to promote osteoblast differentiation of human aortic valve interstitial cells through up-regulating Smad4. Int J Cardiol 243:404–412

  162. 162.

    Sun JY et al (2017) Knockdown of MALAT1 expression inhibits HUVEC proliferation by upregulation of miR-320a and downregulation of FOXM1 expression. Oncotarget 8(37):61499–61509

  163. 163.

    Zhong X et al (2018) MIAT promotes proliferation and hinders apoptosis by modulating miR-181b/STAT3 axis in ox-LDL-induced atherosclerosis cell models. Biomed Pharmacother 97:1078–1085

  164. 164.

    Ye ZM et al (2019) LncRNA MIAT sponges miR-149-5p to inhibit efferocytosis in advanced atherosclerosis through CD47 upregulation. Cell Death Dis 10(2):138

  165. 165.

    Bai Y et al (2019) Modulation of the proliferation/apoptosis balance of vascular smooth muscle cells in atherosclerosis by lncRNA-MEG3 via regulation of miR-26a/Smad1 axis. Int Heart J 60(2):444–450

  166. 166.

    Zhang Y et al (2018) Melatonin prevents endothelial cell pyroptosis via regulation of long noncoding RNA MEG3/miR-223/NLRP3 axis. J Pineal Res 64(2):e12449

  167. 167.

    Miao C et al (2018) LncRNA DIGIT accelerates tube formation of vascular endothelial cells by sponging miR-134. Int Heart J 59(5):1086–1095

  168. 168.

    Ye J et al (2018) LncRBA GSA5, up-regulated by ox-LDL, aggravates inflammatory response and MMP expression in THP-1 macrophages by acting like a sponge for miR-221. Exp Cell Res 369(2):348–355

  169. 169.

    Bao MH et al (2018) Long noncoding RNA LINC00657 acting as a miR-590-3p sponge to facilitate low concentration oxidized low-density lipoprotein-induced angiogenesis. Mol Pharmacol 93(4):368–375

  170. 170.

    Yu C et al (2018) LncRNA TUG1 sponges miR-204-5p to promote osteoblast differentiation through upregulating Runx2 in aortic valve calcification. Cardiovasc Res 114(1):168–179

  171. 171.

    Liu Y et al (2019) Linc00299/miR-490-3p/AURKA axis regulates cell growth and migration in atherosclerosis. Heart Vessels 34(8):1370–1380

  172. 172.

    Tian S et al (2018) LncRNA UCA1 sponges miR-26a to regulate the migration and proliferation of vascular smooth muscle cells. Gene 673:159–166

  173. 173.

    Zhang BY, Jin Z, Zhao Z (2017) Long intergenic noncoding RNA 00305 sponges miR-136 to regulate the hypoxia induced apoptosis of vascular endothelial cells. Biomed Pharmacother 94:238–243

  174. 174.

    Lin Z et al (2017) Let-7e modulates the inflammatory response in vascular endothelial cells through ceRNA crosstalk. Sci Rep 7:42498

  175. 175.

    Zhang L et al (2018) H19 knockdown suppresses proliferation and induces apoptosis by regulating miR-148b/WNT/beta-catenin in ox-LDL -stimulated vascular smooth muscle cells. J Biomed Sci 25(1):11

  176. 176.

    Shan K et al (2016) Role of long non-coding RNA-RNCR3 in atherosclerosis-related vascular dysfunction. Cell Death Dis 7(6):e2248

  177. 177.

    Ebert MS, Sharp PA (2010) MicroRNA sponges: progress and possibilities. RNA 16(11):2043–2050

  178. 178.

    Mukherji S et al (2011) MicroRNAs can generate thresholds in target gene expression. Nat Genet 43(9):854–859

  179. 179.

    Afify AY et al (2019) Competing endogenous RNAs in hepatocellular carcinoma-the Pinnacle of Rivalry. Semin Liver Dis 39:463–475

  180. 180.

    Cai Y, Wan J (2018) Competing endogenous RNA regulations in neurodegenerative disorders: current challenges and emerging insights. Front Mol Neurosci 11:370

  181. 181.

    Ebbesen KK, Hansen TB, Kjems J (2017) Insights into circular RNA biology. RNA Biol 14(8):1035–1045

  182. 182.

    Ebbesen KK, Kjems J, Hansen TB (2016) Circular RNAs: identification, biogenesis and function. Biochim Biophys Acta 1859(1):163–168

  183. 183.

    Qu S et al (2015) Circular RNA: a new star of noncoding RNAs. Cancer Lett 365(2):141–148

  184. 184.

    Zhou MY, Yang JM, Xiong XD (2018) The emerging landscape of circular RNA in cardiovascular diseases. J Mol Cell Cardiol 122:134–139

  185. 185.

    Li M et al (2019) Long noncoding RNA/circular noncoding RNA-miRNA-mRNA axes in cardiovascular diseases. Life Sci 233:116440

  186. 186.

    Altesha MA et al (2019) Circular RNA in cardiovascular disease. J Cell Physiol 234(5):5588–5600

  187. 187.

    Feng J et al (2006) The Evf-2 noncoding RNA is transcribed from the Dlx-5/6 ultraconserved region and functions as a Dlx-2 transcriptional coactivator. Genes Dev 20(11):1470–1484

  188. 188.

    Lujambio A et al (2010) CpG island hypermethylation-associated silencing of non-coding RNAs transcribed from ultraconserved regions in human cancer. Oncogene 29(48):6390–6401

  189. 189.

    Sekino Y et al (2018) Uc.416+ A promotes epithelial-to-mesenchymal transition through miR-153 in renal cell carcinoma. BMC Cancer 18(1):952

  190. 190.

    Braconi C et al (2011) Expression and functional role of a transcribed noncoding RNA with an ultraconserved element in hepatocellular carcinoma. Proc Natl Acad Sci USA 108(2):786–791

  191. 191.

    Wang C et al (2017) TUC.338 promotes invasion and metastasis in colorectal cancer. Int J Cancer 140(6):1457–1464

  192. 192.

    Marini A et al (2017) Ultraconserved long non-coding RNA uc.63 in breast cancer. Oncotarget 8(22):35669–35680

  193. 193.

    Liz J et al (2014) Regulation of pri-miRNA processing by a long noncoding RNA transcribed from an ultraconserved region. Mol Cell 55(1):138–147

  194. 194.

    Xiao L et al (2018) Long noncoding RNA uc.173 promotes renewal of the intestinal mucosa by inducing degradation of microRNA 195. Gastroenterology 154(3):599–611

  195. 195.

    Wang JY et al (2018) Regulation of intestinal epithelial barrier function by long noncoding RNA uc173 through interaction with MicroRNA 29b. Mol Cell Biol 38(13):e00010-18

  196. 196.

    Nishizawa M et al. (2015) Post-transcriptional inducible gene regulation by natural antisense RNA. Front Biosci (Landmark Ed) 20:1–36

  197. 197.

    Gao YF et al (2020) LncRNA FOXD1-AS1 acts as a potential oncogenic biomarker in glioma. CNS Neurosci Ther 26:66–75

  198. 198.

    Hu H et al (2018) Recently evolved tumor suppressor transcript TP73-AS1 functions as sponge of human-specific miR-941. Mol Biol Evol 35(5):1063–1077

  199. 199.

    Wang J et al (2017) TSPAN31 is a critical regulator on transduction of survival and apoptotic signals in hepatocellular carcinoma cells. FEBS Lett 591(18):2905–2918

  200. 200.

    Esnault C, Maestre J, Heidmann T (2000) Human LINE retrotransposons generate processed pseudogenes. Nat Genet 24(4):363–367

  201. 201.

    Kovalenko TF, Patrushev LI (2018) Pseudogenes as functionally significant elements of the genome. Biochemistry (Mosc) 83(11):1332–1349

  202. 202.

    Hu X, Yang L, Mo YY (2018) Role of pseudogenes in tumorigenesis. Cancers (Basel) 10(8):256

  203. 203.

    Wang P et al (2015) miRSponge: a manually curated database for experimentally supported miRNA sponges and ceRNAs. Database (Oxford). https://doi.org/10.1093/database/bav098

  204. 204.

    Poliseno L et al (2010) A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. Nature 465(7301):1033–1038

  205. 205.

    Zhang Z, Harrison P, Gerstein M (2002) Identification and analysis of over 2000 ribosomal protein pseudogenes in the human genome. Genome Res 12(10):1466–1482

  206. 206.

    Li X et al (2019) LncRNA PMS2L2 protects ATDC5 chondrocytes against lipopolysaccharide-induced inflammatory injury by sponging miR-203. Life Sci 217:283–292

  207. 207.

    Wang R et al (2018) Long non-coding RNA FTH1P3 activates paclitaxel resistance in breast cancer through miR-206/ABCB1. J Cell Mol Med 22(9):4068–4075

  208. 208.

    Zhang CZ (2017) Long non-coding RNA FTH1P3 facilitates oral squamous cell carcinoma progression by acting as a molecular sponge of miR-224-5p to modulate fizzled 5 expression. Gene 607:47–55

  209. 209.

    Wang L et al (2013) Pseudogene OCT4-pg4 functions as a natural micro RNA sponge to regulate OCT4 expression by competing for miR-145 in hepatocellular carcinoma. Carcinogenesis 34(8):1773–1781

  210. 210.

    Gao L et al (2017) PTENp1, a natural sponge of miR-21, mediates PTEN expression to inhibit the proliferation of oral squamous cell carcinoma. Mol Carcinog 56(4):1322–1334

  211. 211.

    Zhang R et al (2017) Long non-coding RNA PTENP1 functions as a ceRNA to modulate PTEN level by decoying miR-106b and miR-93 in gastric cancer. Oncotarget 8(16):26079–26089

  212. 212.

    Elbarbary RA, Lucas BA, Maquat LE (2016) Retrotransposons as regulators of gene expression. Science 351(6274):aac7247

  213. 213.

    Wallace N et al (2008) LINE-1 ORF1 protein enhances Alu SINE retrotransposition. Gene 419(1–2):1–6

  214. 214.

    Sciamanna I et al (2014) Regulatory roles of LINE-1-encoded reverse transcriptase in cancer onset and progression. Oncotarget 5(18):8039–8051

  215. 215.

    Mighell AJ, Markham AF, Robinson PA (1997) Alu sequences. FEBS Lett 417(1):1–5

  216. 216.

    Chen LL, Yang L (2017) ALUternative regulation for gene expression. Trends Cell Biol 27(7):480–490

  217. 217.

    Navarro E et al (1999) Expressed sequence tag (EST) phenotyping of HT-29 cells: cloning of ser/thr protein kinase EMK1, kinesin KIF3B, and of transcripts that include Alu repeated elements. Biochim Biophys Acta 1450(3):254–264

  218. 218.

    Daniel C, Behm M, Ohman M (2015) The role of Alu elements in the cis-regulation of RNA processing. Cell Mol Life Sci 72(21):4063–4076

  219. 219.

    Pandey R, Mukerji M (2011) From ‘JUNK’ to just unexplored noncoding knowledge: the case of transcribed Alus. Brief Funct Genomics 10(5):294–311

  220. 220.

    Daskalova E et al (2007) 3′UTR-located ALU elements: donors of potential miRNA target sites and mediators of network miRNA-based regulatory interactions. Evol Bioinform Online 2:103–120

  221. 221.

    Smalheiser NR, Torvik VI (2006) Alu elements within human mRNAs are probable microRNA targets. Trends Genet 22(10):532–536

  222. 222.

    Pandey R et al (2016) Alu-miRNA interactions modulate transcript isoform diversity in stress response and reveal signatures of positive selection. Sci Rep 6:32348

  223. 223.

    Hoffman Y et al (2014) miR-661 downregulates both Mdm2 and Mdm4 to activate p53. Cell Death Differ 21(2):302–309

  224. 224.

    Di Ruocco F et al (2018) Alu RNA accumulation induces epithelial-to-mesenchymal transition by modulating miR-566 and is associated with cancer progression. Oncogene 37(5):627–637

  225. 225.

    Zhao J et al (2015) High-throughput sequencing of RNAs isolated by cross-linking immunoprecipitation (HITS-CLIP) reveals Argonaute-associated microRNAs and targets in Schistosoma japonicum. Parasit Vectors 8:589

  226. 226.

    Imig J et al (2015) miR-CLIP capture of a miRNA targetome uncovers a lincRNA H19-miR-106a interaction. Nat Chem Biol 11(2):107–114

  227. 227.

    Petri R, Jakobsson J (2018) Identifying miRNA targets using AGO-RIPseq. Methods Mol Biol 1720:131–140

  228. 228.

    Sharma E et al (2016) Global mapping of human RNA-RNA interactions. Mol Cell 62(4):618–626

  229. 229.

    Tan SM, Lieberman J (2016) Capture and identification of miRNA targets by biotin pulldown and RNA-seq. Methods Mol Biol 1358:211–228

  230. 230.

    Hannigan MM, Zagore LL, Licatalosi DD (2018) Mapping transcriptome-wide protein-RNA interactions to elucidate RNA regulatory programs. Quant Biol 6(3):228–238

  231. 231.

    Clement T, Salone V, Rederstorff M (2015) Dual luciferase gene reporter assays to study miRNA function. Methods Mol Biol 1296:187–198

  232. 232.

    Monga I, Kumar M (2019) Computational resources for prediction and analysis of functional miRNA and their targetome. Methods Mol Biol 1912:215–250

  233. 233.

    Riffo-Campos AL, Riquelme I, Brebi-Mieville P (2016) Tools for sequence-based miRNA target prediction: what to choose? Int J Mol Sci 17(12):1987

  234. 234.

    Ning S, Li X (2018) Non-coding RNA resources. Adv Exp Med Biol 1094:1–7

  235. 235.

    Roberts JT, Borchert GM (2017) Computational prediction of MicroRNA target genes, target prediction databases, and web resources. Methods Mol Biol 1617:109–122

  236. 236.

    Fridrich A, Hazan Y, Moran Y (2019) Too many false targets for MicroRNAs: challenges and pitfalls in prediction of miRNA targets and their gene ontology in model and non-model organisms. BioEssays 41(4):e1800169

  237. 237.

    Wagner M et al (2014) MicroRNA target prediction: theory and practice. Mol Genet Genomics 289(6):1085–1101

  238. 238.

    Lu TP et al (2012) miRSystem: an integrated system for characterizing enriched functions and pathways of microRNA targets. PLoS ONE 7(8):e42390

  239. 239.

    Dweep H, Gretz N (2015) miRWalk2.0: a comprehensive atlas of microRNA-target interactions. Nat Methods 12(8):697

  240. 240.

    Creighton CJ, Reid JG, Gunaratne PH (2009) Expression profiling of microRNAs by deep sequencing. Brief Bioinform 10(5):490–497

  241. 241.

    Andres-Leon E, Rojas AM (2019) miARma-Seq, a comprehensive pipeline for the simultaneous study and integration of miRNA and mRNA expression data. Methods 152:31–40

  242. 242.

    Edgar R, Domrachev M, Lash AE (2002) Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 30(1):207–210

  243. 243.

    Zhang Y et al (2018) Effects of icariin on atherosclerosis and predicted function regulatory network in apoe deficient mice. Biomed Res Int 2018:9424186

  244. 244.

    Gene Ontology, C (2015) Gene Ontology Consortium: going forward. Nucleic Acids Res 43(Database issue):D1049–D1056

  245. 245.

    Khyzha N et al (2017) Epigenetics of atherosclerosis: emerging mechanisms and methods. Trends Mol Med 23(4):332–347

  246. 246.

    Parikh N, Frishman WH (2010) Liver x receptors: a potential therapeutic target for modulating the atherosclerotic process. Cardiol Rev 18(6):269–274

  247. 247.

    Wang HX, Zhao YX (2016) Prediction of genetic risk factors of atherosclerosis using various bioinformatic tools. Genet Mol Res 15(2):gmr7347

  248. 248.

    Su Q, Lv X (2019) Revealing new landscape of cardiovascular disease through circular RNA-miRNA-mRNA axis. Genomics. https://doi.org/10.1016/j.ygeno.2019.10.006

  249. 249.

    He L et al (2018) Uncovering novel landscape of cardiovascular diseases and therapeutic targets for cardioprotection via long noncoding RNA-miRNA-mRNA axes. Epigenomics 10(5):661–671

  250. 250.

    Kozomara A, Birgaoanu M, Griffiths-Jones S (2019) miRBase: from microRNA sequences to function. Nucleic Acids Res 47(D1):D155–D162

  251. 251.

    Chou CH et al (2018) miRTarBase update 2018: a resource for experimentally validated microRNA-target interactions. Nucleic Acids Res 46(D1):D296–D302

  252. 252.

    Sethupathy P, Corda B, Hatzigeorgiou AG (2006) TarBase: a comprehensive database of experimentally supported animal microRNA targets. RNA 12(2):192–197

  253. 253.

    Paraskevopoulou MD et al (2013) DIANA-microT web server v5.0: service integration into miRNA functional analysis workflows. Nucleic Acids Res 41(Web Server issue):W169–W173

  254. 254.

    Blin K et al (2015) DoRiNA 2.0–upgrading the doRiNA database of RNA interactions in post-transcriptional regulation. Nucleic Acids Res 43(Database issue):D160–D167

  255. 255.

    John B et al (2004) Human MicroRNA targets. PLoS Biol 2(11):e363

  256. 256.

    Tsang JS, Ebert MS, van Oudenaarden A (2010) Genome-wide dissection of microRNA functions and cotargeting networks using gene set signatures. Mol Cell 38(1):140–153

  257. 257.

    Wong N, Wang X (2015) miRDB: an online resource for microRNA target prediction and functional annotations. Nucleic Acids Res 43(Database issue):D146–D152

  258. 258.

    Vejnar CE, Zdobnov EM (2012) MiRmap: comprehensive prediction of microRNA target repression strength. Nucleic Acids Res 40(22):11673–11683

  259. 259.

    Hsu SD et al (2008) miRNAMap 2.0: genomic maps of microRNAs in metazoan genomes. Nucleic Acids Res 36(Database issue):D165–D169

  260. 260.

    Krek A et al (2005) Combinatorial microRNA target predictions. Nat Genet 37(5):495–500

  261. 261.

    Kertesz M et al (2007) The role of site accessibility in microRNA target recognition. Nat Genet 39(10):1278–1284

  262. 262.

    Chang TH et al (2013) An enhanced computational platform for investigating the roles of regulatory RNA and for identifying functional RNA motifs. BMC Bioinform 14(Suppl 2):S4

  263. 263.

    Miranda KC et al (2006) A pattern-based method for the identification of MicroRNA binding sites and their corresponding heteroduplexes. Cell 126(6):1203–1217

  264. 264.

    Rehmsmeier M et al (2004) Fast and effective prediction of microRNA/target duplexes. RNA 10(10):1507–1517

  265. 265.

    Wu X, Watson M (2009) CORNA: testing gene lists for regulation by microRNAs. Bioinformatics 25(6):832–833

  266. 266.

    Nam S et al (2009) MicroRNA and mRNA integrated analysis (MMIA): a web tool for examining biological functions of microRNA expression. Nucleic Acids Res 37(Web Server issue):W356–W362

  267. 267.

    Paraskevopoulou MD et al (2013) DIANA-LncBase: experimentally verified and computationally predicted microRNA targets on long non-coding RNAs. Nucleic Acids Res 41(Database issue):D239–D245

  268. 268.

    Eraslan G et al (2019) Single-cell RNA-seq denoising using a deep count autoencoder. Nat Commun 10(1):390

  269. 269.

    Eraslan G et al (2019) Deep learning: new computational modelling techniques for genomics. Nat Rev Genet 20(7):389–403

  270. 270.

    Yue T, Wang H (2018) arXiv:1802.00810v2 [q-bio.GN] 

  271. 271.

    Jaganathan K et al (2019) Predicting splicing from primary sequence with deep learning. Cell 176(3):535–548.e24

Download references

Acknowledgements

We thank REDinREN and the CERCA program/Generalitat de Catalunya for institutional support.

Funding

This study has been partially funded by Instituto de Salud Carlos III (Co-funded by European Regional Development Fund. ERDF, a way to build Europe) through the project PI 11/00556 and 18/01108 to MH and by REDinREN (12/0021).

Author information

Affiliations

Authors

Contributions

Conception and design of the work (EN and MH), Funding (MH), Resources (AM, JMC and JT), Writing the original draft (EN and MH), Manuscript revision and editing (EN, AM, JMC and MH). All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Estanislao Navarro or Miguel Hueso.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests nor economic interests in any of the companies here cited.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Navarro, E., Mallén, A., Cruzado, J.M. et al. Unveiling ncRNA regulatory axes in atherosclerosis progression. Clin Trans Med 9, 5 (2020). https://doi.org/10.1186/s40169-020-0256-3

Download citation

Keywords

  • Dark transcriptome
  • miRNA
  • lncRNAs
  • Alternative 3′UTRs
  • Regulatory RNA networks
  • Atherosclerosis